This is a cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract, valued at $30,920,844.79, is for an Expanded Access Protocol for ZMapp, a medical countermeasure against infectious diseases and biothreats such as Ebola, Sudan, Marburg, and botulinum neurotoxin. The contract has no set-aside designation and has an ultimate completion date of December 31, 2027. Mapp Biopharmaceutical has a history of receiving significant federal funding, including an $856.7 million contract for therapeutics addressing Ebola, Sudan, and Marburg viruses, a $299 million contract for developing MBP091 as an immunotherapy for Marburg virus infection, and other contracts related to medical countermeasure development and clinical trials. The company's expertise in infectious disease research and countermeasure development positions it as a crucial partner in the U.S. government's efforts to prepare for and respond to public health emergencies.